Alcon (ALC - Free Report) reported $2.4 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 9.2%. EPS of $0.69 for the same period compares to $0.63 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of +2.45%. The company delivered an EPS surprise of +11.29%, with the consensus EPS estimate being $0.62.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Total Surgical: $1.38 billion versus the four-analyst average estimate of $1.34 billion. The reported number represents a year-over-year change of +6.6%.
- Net Sales- Total Vision care: $1.02 billion versus $987.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.
- Net Sales- Total Surgical- Consumables: $714 million versus the four-analyst average estimate of $675.99 million.
- Net Sales- Total Surgical- Implantables: $437 million versus the four-analyst average estimate of $445.92 million.
- Net Sales- Total Vision Care- Contact lenses: $594 million versus the four-analyst average estimate of $588.05 million.
- Net Sales- Total Vision Care- Ocular health: $426 million versus the four-analyst average estimate of $399.12 million.
- Net Sales- Total Surgical- Equipment/other: $231 million versus the four-analyst average estimate of $217.35 million.
View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned -3.3% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Alcon (ALC - Free Report) reported $2.4 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 9.2%. EPS of $0.69 for the same period compares to $0.63 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of +2.45%. The company delivered an EPS surprise of +11.29%, with the consensus EPS estimate being $0.62.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Total Surgical: $1.38 billion versus the four-analyst average estimate of $1.34 billion. The reported number represents a year-over-year change of +6.6%.
- Net Sales- Total Vision care: $1.02 billion versus $987.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.
- Net Sales- Total Surgical- Consumables: $714 million versus the four-analyst average estimate of $675.99 million.
- Net Sales- Total Surgical- Implantables: $437 million versus the four-analyst average estimate of $445.92 million.
- Net Sales- Total Vision Care- Contact lenses: $594 million versus the four-analyst average estimate of $588.05 million.
- Net Sales- Total Vision Care- Ocular health: $426 million versus the four-analyst average estimate of $399.12 million.
- Net Sales- Total Surgical- Equipment/other: $231 million versus the four-analyst average estimate of $217.35 million.
View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned -3.3% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on ALC - FREE